Insider · CIK 0001524858
Joshua Silverman
Files at FABC (StableX Technologies, Inc.), PMCB (PharmaCyte Biotech, Inc.), QCLS (Q/C TECHNOLOGIES, INC.), FEMY (FEMASYS INC), TAOX (TAO Synergies Inc.), PTPI (Petros Pharmaceuticals, Inc.). First filing Jan 7, 2026, latest Jan 7, 2026.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
PMCB: PharmaCyte Biotech, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 48Moderate | PharmaCyte Biotech, Inc. | $80k 100,000 shares | +32% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 10, 2026 | QCLS Q/C TECHNOLOGIES, INC. | AGrant or award Common Stock | +16,620 | $0.00 | $0 | 133,455 | 11 d ago |
| Apr 13, 2026 | QCLS Q/C TECHNOLOGIES, INC. | AGrant or award Common Stock | +16,806 | $0.00 | $0 | 116,835 | 11 d ago |
| Apr 13, 2026 | QCLS Q/C TECHNOLOGIES, INC. | AGrant or award Employee Stock Option (Right to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | 11 d ago |
| Oct 1, 2026 | QCLS Q/C TECHNOLOGIES, INC. | AGrant or award Common Stock | +77,390 | $0.00 | $0 | 210,845 | 11 d ago |
| Jan 5, 2026 | PMCB PharmaCyte Biotech, Inc. | POpen-market purchase Common Stock | +30,000 | $0.78 | $23k | 346,250 | Jan 7, 2026 |
| Jan 6, 2026 | PMCB PharmaCyte Biotech, Inc. | POpen-market purchase Common Stock | +30,000 | $0.79 | $24k | 376,250 | Jan 7, 2026 |
| Jan 7, 2026 | PMCB PharmaCyte Biotech, Inc. | POpen-market purchase Common Stock | +40,000 | $0.83 | $33k | 416,250 | Jan 7, 2026 |
| Jan 2, 2026 | PTPI Petros Pharmaceuticals, Inc. | AGrant or award Common Stock | +4,375,000 | $0.00 | $0 | 4,415,450 | Jan 2, 2026 |
| Dec 12, 2025 | PMCB PharmaCyte Biotech, Inc. | AGrant or award Common Stock | +575,000 | $0.00 | $0 | 575,000 | Dec 12, 2025 |
| Dec 12, 2025 | PMCB PharmaCyte Biotech, Inc. | FTax withholding Common Stock | -258,750 | $1.02 | $264k | 316,250 | Dec 12, 2025 |
| Nov 14, 2025 | QCLS Q/C TECHNOLOGIES, INC. | AGrant or award Common stock | +91,356 | $0.00 | $0 | 100,029 | Nov 14, 2025 |
| Oct 31, 2025 | FABC StableX Technologies, Inc. | AGrant or award Employee Stock Option (Right to Buyderivative | +220,513 | $0.00 | $0 | 220,513 | Oct 31, 2025 |
| Oct 17, 2025 | TAOX TAO Synergies Inc. | AGrant or award Common Stock, par value $0.0001 per share | +100,000 | $0.00 | $0 | 126,681 | Oct 17, 2025 |
| Oct 17, 2025 | TAOX TAO Synergies Inc. | FTax withholding Common Stock, par value $0.0001 per share | -40,000 | $7.23 | $289k | 86,681 | Oct 17, 2025 |
| Aug 6, 2025 | TAOX TAO Synergies Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +36,000 | $0.00 | $0 | 36,000 | Oct 17, 2025 |
| Oct 3, 2025 | QCLS Q/C TECHNOLOGIES, INC. | AGrant or award Common stock | +8,644 | $0.00 | $0 | 8,673 | Oct 6, 2025 |
| Jun 30, 2025 | TAOX TAO Synergies Inc. | AGrant or award Common Stock, par value $0.0001 per share | +41,919 | $0.00 | $0 | 43,449 | Jul 2, 2025 |
| Jun 30, 2025 | TAOX TAO Synergies Inc. | FTax withholding Common Stock, par value $0.0001 per share | -16,768 | $7.85 | $132k | 26,681 | Jul 2, 2025 |
| Jun 25, 2025 | FEMY FEMASYS INC | AGrant or award Stock Option (Right to Buy)derivative | +17,600 | $0.00 | $0 | 17,600 | Jun 27, 2025 |
| Dec 2, 2024 | FABC StableX Technologies, Inc. | DDisposition to issuer Common Stock | -6,166 | $0.00 | $0 | 43,271 | Dec 2, 2024 |
| Dec 2, 2024 | FABC StableX Technologies, Inc. | AGrant or award Common Stock | +146,052 | $0.00 | $0 | 189,323 | Dec 2, 2024 |
| Dec 2, 2024 | FABC StableX Technologies, Inc. | MOption exercise Cash-Settled Restricted Stock Unitsderivative | +97,368 | $0.00 | $0 | 97,368 | Dec 2, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.